CA-ILLUMINA-VENTURES
4.8.2022 14:02:04 CEST | Business Wire | Press release
Illumina Ventures , an independently-managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN) today announced the addition of four new members to its European team. Arnaud Autret, PhD, MSc, will be Principal and Head of European Operations, William Byrne, PhD, be an Associate – Europe, and Ronan Byrne and Ivan Coulter, PhD, BSc, will serve as Venture Advisors – Europe.
“We are already supporting some great companies in Ireland, France and the UK. The addition of Arnaud, William, Ronan and Ivan to our team will enable us build upon our successes and pursue even more ambitious genomics-focused projects in Europe,” said Nick Naclerio, PhD, Illumina Ventures Founding Partner.
Arnaud brings more than 15 years of financial and investment experience in the life sciences and biopharmaceutical industries, as well as scientific knowledge, to his new position. Before joining the Company, Arnaud was Investment Director in the biotechnology team of M Ventures in Amsterdam, which is the corporate venture capital arm of Merck KGaA. Previously, he worked as the Senior Associate in the Life Sciences team at Seventure Partners in Paris, as well as a senior financial auditor in the healthcare business unit at KPMG, also in Paris. Arnaud completed his post-doctoral work in oncology at the Trinity College Dublin after receiving his PhD in immunology from the Pasteur Institute in Paris. Arnaud also holds a MSc in finance from ESCP Business School, in Paris. Arnaud is based in Amsterdam.
Before joining Illumina Ventures, William was Head of Biotechnology at NEOM, a futuristic megacity that will be located in Saudi Arabia and rely on renewable energy and new technology for sustainable living. William led the efforts to establish NEOM as a global biotech hub with a focus on precision medicine. Previously, he worked as a consultant in the healthcare and life sciences industries providing clients located in the Middle East and Europe with investment, research, go-to-market and product launch strategies. William earned a PhD in tumor immunology and a Bachelor of Pharmacy degree at University College Cork in Ireland. He also holds a Master of Business Administration degree from INSEAD in France. William is based in Cork.
As a highly experienced CEO, Ronan has built and led several companies over his career that he later sold to multinational companies. Over the last decade, he has focused his efforts on the commercialization of innovations in the life sciences industry. He was CEO of ClearSight Innovations (Ophthalmic Diagnostic technologies) which sold to an industry leader and is currently the CEO and Co-founder of Pharma Latch in Dublin, which is developing a revolutionary intradermal delivery technology for drugs, vaccines, and a range of immunotherapies; he is also Business Mentor at Enterprise Ireland. Ronan received both a Master of Business Administration degree and a BA in Economics and Politics from University College Dublin.
Ivan is an entrepreneur with experience in translating early-stage innovations into clinical development programs. As a pharmacologist, he understands the importance of aligning molecular pathways with appropriate therapeutics and diagnostics. He is currently Founder and Managing Director of Eden BioPharma Limited in Dublin. Ivan was also Founder and CEO of Sigmoid Pharma Limited, where he focused on the development of an integrated drug delivery platform within the gastrointestinal tract. As a consultant, he has advised academics and entrepreneurs in setting up companies, developing fundable strategies and building multidisciplinary teams. Ivan obtained his MBA from the Johnson Graduate School of Management at Cornell University in New York and completed his post-doctoral fellowship in developmental biology at the Institut Curie in Paris after receiving a PhD in cancer research and BSc in pharmacology from University College Dublin. He and Ronan are based in Dublin.
“We are committed to supporting new and existing early-stage startups in Europe that are developing innovative clinical diagnostics and life science research tools, as well as therapeutic platforms, digital health initiatives and genomics applications,” said Wouter Meuleman, PhD, Illumina Ventures Partner. “We are excited to have Arnaud, William, Ronan and Ivan join in our efforts.”
About Illumina Ventures
Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome. As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, and personal wellness.
For more information, visit illuminaventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom